ALK inhibitor 2 is primarily utilized in the field of oncology for the treatment of cancers associated with anaplastic lymphoma kinase (ALK) gene mutations. It works by selectively inhibiting the activity of ALK, which is often aberrantly activated in certain types of cancers, such as non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL). By blocking ALK signaling pathways, the inhibitor helps to halt the proliferation of cancer cells and can induce apoptosis, thereby slowing tumor growth and progression. It is often used in targeted therapy regimens, particularly for patients who have developed resistance to other ALK inhibitors. Additionally, it is being studied in clinical trials for its efficacy in treating other ALK-positive malignancies and its potential use in combination therapies to enhance overall treatment outcomes.